These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19671594)

  • 1. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
    Torras J; Herrero-Fresneda I; Gulias O; Flaquer M; Vidal A; Cruzado JM; Lloberas N; Franquesa Ml; Grinyó JM
    Nephrol Dial Transplant; 2009 Dec; 24(12):3632-40. PubMed ID: 19671594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling.
    Shibata S; Nagase M; Fujita T
    J Am Soc Nephrol; 2006 Mar; 17(3):754-64. PubMed ID: 16452496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
    Bonegio RG; Fuhro R; Wang Z; Valeri CR; Andry C; Salant DJ; Lieberthal W
    J Am Soc Nephrol; 2005 Jul; 16(7):2063-72. PubMed ID: 15917339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
    Fukuda A; Fujimoto S; Iwatsubo S; Kawachi H; Kitamura K
    Nephrology (Carlton); 2010 Apr; 15(3):321-6. PubMed ID: 20470301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bone mesenchymal stem cell transplantation repairs glomerular podocytes in rats with puromycin aminonucleoside-induced nephrosis].
    Yang HD; Dong C; Guan FJ; Gao LL; Zhao T; Feng BF
    Zhongguo Dang Dai Er Ke Za Zhi; 2010 Jun; 12(6):483-7. PubMed ID: 20540862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome.
    Koshikawa M; Mukoyama M; Mori K; Suganami T; Sawai K; Yoshioka T; Nagae T; Yokoi H; Kawachi H; Shimizu F; Sugawara A; Nakao K
    J Am Soc Nephrol; 2005 Sep; 16(9):2690-701. PubMed ID: 15987752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
    Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
    Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key molecular events in puromycin aminonucleoside nephrosis rats.
    Guan N; Ding J; Deng J; Zhang J; Yang J
    Pathol Int; 2004 Sep; 54(9):703-11. PubMed ID: 15363039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
    Diekmann F; Rovira J; Carreras J; Arellano EM; Bañón-Maneus E; Ramírez-Bajo MJ; Gutiérrez-Dalmau A; Brunet M; Campistol JM
    J Am Soc Nephrol; 2007 Oct; 18(10):2653-60. PubMed ID: 17804674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin induced ultrastructural and molecular alterations in glomerular podocytes in healthy mice.
    Stylianou K; Petrakis I; Mavroeidi V; Stratakis S; Kokologiannakis G; Lioudaki E; Liotsi C; Kroustalakis N; Vardaki E; Stratigis S; Perakis K; Kyriazis J; Nakopoulou L; Daphnis E
    Nephrol Dial Transplant; 2012 Aug; 27(8):3141-8. PubMed ID: 22290989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway.
    Xiao H; Shi W; Liu S; Wang W; Zhang B; Zhang Y; Xu L; Liang X; Liang Y
    Am J Nephrol; 2009; 30(1):34-43. PubMed ID: 19202327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
    Fujimura T; Yamagishi S; Ueda S; Fukami K; Shibata R; Matsumoto Y; Kaida Y; Hayashida A; Koike K; Matsui T; Nakamura K; Okuda S
    Nephrol Dial Transplant; 2009 May; 24(5):1397-406. PubMed ID: 19042927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria.
    Yu D; Petermann A; Kunter U; Rong S; Shankland SJ; Floege J
    J Am Soc Nephrol; 2005 Jun; 16(6):1733-41. PubMed ID: 15829708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
    Ko HT; Yin JL; Wyburn K; Wu H; Eris JM; Hambly BD; Chadban SJ
    Nephrol Dial Transplant; 2013 Feb; 28(2):327-36. PubMed ID: 23229928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction.
    Rovira J; Arellano EM; Carreras J; Campos B; Vodenik B; Bañón-Maneus E; Ramírez-Bajo MJ; Moya-Rull D; Solé-González A; Hernández A; Revuelta I; Quintana LF; Howat WJ; Campistol JM; Diekmann F
    Transplantation; 2009 Sep; 88(5):646-52. PubMed ID: 19741461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats.
    Matsui I; Hamano T; Tomida K; Inoue K; Takabatake Y; Nagasawa Y; Kawada N; Ito T; Kawachi H; Rakugi H; Imai E; Isaka Y
    Nephrol Dial Transplant; 2009 Aug; 24(8):2354-61. PubMed ID: 19297354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases.
    Szeto CC; Lai KB; Chow KM; Szeto CY; Yip TW; Woo KS; Li PK; Lai FM
    Clin Chim Acta; 2005 Nov; 361(1-2):182-90. PubMed ID: 15996647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
    Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
    Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models.
    Shen X; Jiang H; Ying M; Xie Z; Li X; Wang H; Zhao J; Lin C; Wang Y; Feng S; Shen J; Weng C; Lin W; Wang H; Zhou Q; Bi Y; Li M; Wang L; Zhu T; Huang X; Lan HY; Zhou J; Chen J
    Sci Rep; 2016 Sep; 6():32087. PubMed ID: 27580845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.